Key clinical point: In SJIA patients with refractory macrophage activation syndrome, emapalumab rapidly induced a complete response.
Major finding: All six of six initial SJIA patients with MAS who failed glucocorticoids had a complete response in an ongoing pilot study.
Data source: An ongoing, multicenter, open-label, pilot study of six patients enrolled so far.
Disclosures: Dr. De Benedetti reported financial relationships with multiple pharmaceutical companies, including SOBI, the sponsor of this study.
De Benedetti F et al. Ann Rheum Dis. Jun 2019;78(Suppl2):178. Abstract OPO204, doi: 10.1136/annrheumdis-2019-eular.3341.